Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model
- PMID: 12692788
- DOI: 10.1002/pros.10215
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model
Abstract
Background: Animal models that closely mimic clinical disease can be exploited to hasten the pace of translational research. To this end, we have defined windows of opportunity in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of prostate cancer as a paradigm for designing pre-clinical trials.
Methods: The incidence of cancer, metastasis, and distribution of pathology were examined as a function of time in TRAMP mice. The expression of various markers of differentiation were characterized.
Results: The TRAMP model develops progressive, multifocal, and heterogeneous disease. Each lobe of the prostate progressed at a different rate. Cytokeratin 8, E-cadherin, and androgen receptor (AR) were expressed during cancer progression but levels were reduced or absent in late stage disease. A distinct epithelial to neuroendocrine (ENT) shift was observed to be a stochastic event related to prostate cancer progression in TRAMP.
Conclusions: This study will serve as the basis for the rational design of pre-clinical studies with genetically engineered mouse models.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
-
Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.Prostate. 2008 Apr 1;68(5):548-62. doi: 10.1002/pros.20714. Prostate. 2008. PMID: 18247402
-
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.Cancer Res. 1997 Aug 15;57(16):3325-30. Cancer Res. 1997. PMID: 9269988
-
Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.Prostate. 2007 Mar 1;67(4):396-404. doi: 10.1002/pros.20511. Prostate. 2007. PMID: 17187397
-
Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.J Cell Biochem. 2005 Feb 1;94(2):279-97. doi: 10.1002/jcb.20339. J Cell Biochem. 2005. PMID: 15565647 Review.
-
Genetically modified mice and their use in developing therapeutic strategies for prostate cancer.J Urol. 2004 Jul;172(1):12-9. doi: 10.1097/01.ju.0000132122.93436.aa. J Urol. 2004. PMID: 15201729 Review.
Cited by
-
Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.Cell Cycle. 2013 May 15;12(10):1598-604. doi: 10.4161/cc.24741. Epub 2013 Apr 25. Cell Cycle. 2013. PMID: 23624841 Free PMC article.
-
β-Carotene 9',10' Oxygenase Modulates the Anticancer Activity of Dietary Tomato or Lycopene on Prostate Carcinogenesis in the TRAMP Model.Cancer Prev Res (Phila). 2017 Feb;10(2):161-169. doi: 10.1158/1940-6207.CAPR-15-0402. Epub 2016 Nov 2. Cancer Prev Res (Phila). 2017. PMID: 27807077 Free PMC article.
-
Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic.Cells. 2022 Nov 30;11(23):3868. doi: 10.3390/cells11233868. Cells. 2022. PMID: 36497126 Free PMC article. Review.
-
The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression.Front Oncol. 2022 Jun 27;12:905398. doi: 10.3389/fonc.2022.905398. eCollection 2022. Front Oncol. 2022. PMID: 35832549 Free PMC article. Review.
-
Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer.Mol Cancer Res. 2014 Oct;12(10):1470-9. doi: 10.1158/1541-7786.MCR-13-0490-T. Epub 2014 Jul 22. Mol Cancer Res. 2014. PMID: 25053806 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous